Presented by:
Keith Crawford, MD, PhD, PHEN, Director of Clinical Trials and Patient Education

Neal Shore, MD, FACS, US Chief Medical Officer of Surgery and Oncology
GenesisCare USA, Director, CPI, Carolina Urologic Research Center

Dr. Keith Crawford, PHEN’s Director of Clinical Trials and Patient Education, and Dr. Neal Shore, US Chief Medical Officer of Surgery and Oncology at GenesisCare USA, outlined innovative clinical trials to treat hormone-sensitive prostate cancer during a live webinar. Dr. Crawford discussed the racial disparity in prostate cancer along with androgen deprivation therapy, the genetic mutations behind cancer, the PROFOUND study, and the medication Talazoparib. Dr. Neal Shore outlined the TALAPRO-3 study and emphasized the need to increase clinical trial participation among the African American population. The speakers also answered questions at the end of the session.

Clinical Trials, Prostate Cancer Treatments

#AfricanAmericanMen, #AndrogenDeprivationTherapy, #CancerTrials, #ClinicalResearch, #ClinicalTrials, #Genetics, #HormoneSensitiveProstateCancer, #MetastaticCancer, #ProstateCancer, #ProstateCancerAwareness, #ProstateCancerDisparity, #RacialDisparity, #Talazoparib

Posted on March 10, 2022

Hormone Sensitive Prostate Cancer Webinar

Leave a Reply